Lifecore Biomedical, Inc. · NASDAQ:LFCR
Lifecore Biomedical — FY2023 Earnings Presentation
5 slides from Lifecore Biomedical's earnings presentation, Mar 20, 2024
Slide 1: Supplemental Financial Information: FY23 10-K Restatement Summary
Lifecore Biomedical, Inc March 2024 Supplemental Financial Information FY23 10-K Restatement Summary Exhbit 99.2
Slide 2: FY23 Form 10-K Restatement Summary
FY23 Form 10-K Restatement Summary The FY23 Annual Report on Form 10-K filing contains the restatement of previously issued consolidated financial statements as of and for the fiscal years ended May 29, 2022 (“FY22”) and May 30, 2021 (“FY21”) included in the Company’s Annual Report on Form 10-K/A fo
Slide 3: Non-GAAP Measures
This supplemental financial presentation contains non-GAAP financial information, including with respects to EBITDA, adjusted EBITDA, Lifecore segment adjusted EBITDA, and Other segment adjusted EBITDA. The Company has included reconciliations of these non-GAAP financial measures to their respective
Slide 4: Lifecore Segment Restated Financials
4 Lifecore Segment Restated Financials Nine Months Ended Quarter Ended Year Ended ($ in thousands) May 30, 2021 May 29, 2022 August 28, 2022 November 27, 2022 February 26, 2023 February 26, 2023 May 28, 2023 (5) May 28, 2023 (5) Period Ended As Reported (1) Net sales 98,087$ 109,320$ 23,703$ 21,691$
Slide 5: Lifecore Segment Reconciliation: Net Income (Loss) from Continuing Operations to Adjusted EBITDA
Lifecore Segment Reconciliation: Net Income (Loss) from Continuing Operations to Adjusted EBITDA 5 Nine Months Ended Quarter Ended Year Ended ($ in thousands) May 30, 2021 May 29, 2022 August 28, 2022 November 27, 2022 February 26, 2023 February 26, 2023 May 28, 2023 (5) May 28, 2023 (5) Period Ende
Lifecore Biomedical, Inc. \de\ — FY2023 Earnings Presentation on 6ix